Godlike Productions - Reply to Thread

Users Online Now: 1,796 (Who's On?)	Visitors Today: 1,463,777
Pageviews Today: 2,082,414	Threads Today: 513	Posts Today: 9,731
04:21 PM

REPLY TO THREAD

Subject Shingles Shots to contain MRNA soon: Pfizer

User Name

Font color: Font:

In accordance with industry accepted best practices we ask that users limit their copy / paste of copyrighted material to the relevant portions of the article you wish to discuss and no more than 50% of the source material, provide a link back to the original article and provide your original comments / criticism in your post with the article.

[quote:Brass Clockwork:MV81MjY5ODgxXzJGRDdGRkUy]
<50%
https://www.washingtonexaminer.com/policy/healthcare/covid-19-vaccine-developers-to-use-mrna-technology-for-better-shingles-inoculation

'Clinical trials of the vaccine for shingles, a debilitating disease triggered by a chronic form of the virus that causes chickenpox, will begin in the second half of the year, according to an announcement from the companies (2022)."

"Infectious disease experts lauded the development of mRNA COVID-19 vaccines, which can be tailored in labs relatively easily to target specific pathogens. Because the mRNA is produced in a chemical process rather than a biological one, like the flu vaccine, mRNA production can be scaled up quickly to produce massive quantities of product, as seen during the massive vaccine rollout early last year."

[b]Pfizer-BioNTech’s new vaccine would compete with GlaxoSmithKline's two-dose vaccine Shingrix, which was approved by the Food and Drug Administration in 2017.[/b]
[/quote]

Original Message <50%
[link to www.washingtonexaminer.com (secure)]

'Clinical trials of the vaccine for shingles, a debilitating disease triggered by a chronic form of the virus that causes chickenpox, will begin in the second half of the year, according to an announcement from the companies (2022)."

"Infectious disease experts lauded the development of mRNA COVID-19 vaccines, which can be tailored in labs relatively easily to target specific pathogens. Because the mRNA is produced in a chemical process rather than a biological one, like the flu vaccine, mRNA production can be scaled up quickly to produce massive quantities of product, as seen during the massive vaccine rollout early last year."

Pfizer-BioNTech’s new vaccine would compete with GlaxoSmithKline's two-dose vaccine Shingrix, which was approved by the Food and Drug Administration in 2017.

Pictures (click to insert)





\| Next Page >>